2025 United States Anti-Obesity Drugs Market Revenue Opportunities Report
Description
The 2025 United States Anti-Obesity Drugs Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Obesity Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the U.S. anti-obesity drugs market are Novo Nordisk, Eli Lilly, GlaxoSmithKline (GSK), and Currax Pharmaceuticals. Novo Nordisk dominates this market with its GLP-1 receptor agonist Wegovy (semaglutide), approved for chronic weight management, which has driven significant sales growth in 2024. Eli Lilly follows closely with tirzepatide (Mounjaro/Zepbound), noted for its efficacy in weight reduction and diabetes risk reduction. GSK markets the over-the-counter anti-obesity drug Alli (orlistat), targeting a broader consumer base. Currax Pharmaceuticals is also a key market player focused on novel obesity drug development.
These companies lead a dynamic and rapidly growing market in North America, driven by the rise in obesity prevalence and advancements in drug innovation, especially in GLP-1 and dual agonist therapies. Novo Nordisk and Eli Lilly’s GLP-1 and dual agonist drugs have revolutionized treatment, capturing large market shares through significant efficacy in weight loss and metabolic disease risk reduction. The market growth is further supported by government initiatives, increased awareness, and strategic partnerships such as Roche’s collaboration with Zealand Pharma to develop new agents. Supply shortages and shifting prescription patterns reflect strong demand for these therapies in clinical practice through both specialized and primary care providers.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Obesity Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the U.S. anti-obesity drugs market are Novo Nordisk, Eli Lilly, GlaxoSmithKline (GSK), and Currax Pharmaceuticals. Novo Nordisk dominates this market with its GLP-1 receptor agonist Wegovy (semaglutide), approved for chronic weight management, which has driven significant sales growth in 2024. Eli Lilly follows closely with tirzepatide (Mounjaro/Zepbound), noted for its efficacy in weight reduction and diabetes risk reduction. GSK markets the over-the-counter anti-obesity drug Alli (orlistat), targeting a broader consumer base. Currax Pharmaceuticals is also a key market player focused on novel obesity drug development.
These companies lead a dynamic and rapidly growing market in North America, driven by the rise in obesity prevalence and advancements in drug innovation, especially in GLP-1 and dual agonist therapies. Novo Nordisk and Eli Lilly’s GLP-1 and dual agonist drugs have revolutionized treatment, capturing large market shares through significant efficacy in weight loss and metabolic disease risk reduction. The market growth is further supported by government initiatives, increased awareness, and strategic partnerships such as Roche’s collaboration with Zealand Pharma to develop new agents. Supply shortages and shifting prescription patterns reflect strong demand for these therapies in clinical practice through both specialized and primary care providers.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
